We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




AI Could Help Identify Early Skin Cancer

By LabMedica International staff writers
Posted on 05 Sep 2017
Newly developed technology uses artificial intelligence (AI) to help detect melanoma skin cancer earlier than current methods and to help reduce the number of unnecessary biopsies. More...
The AI-based method employs machine-learning software to analyze images of skin lesions and to provide doctors with objective data on telltale biomarkers of melanoma.

"This could be a very powerful tool for skin cancer clinical decision support," said Alexander Wong, professor at University of Waterloo (Waterloo, ON, Canada), "The more interpretable information there is, the better the decisions are." Prof. Wong developed the technology in collaboration with Daniel Cho, former PhD student at Waterloo, David Clausi, professor at Waterloo, and Farzad Khalvati, adjunct professor at Waterloo and scientist at Sunnybrook.

Currently, dermatologists largely rely on subjective visual examinations of skin lesions (e.g. moles) to decide if patients should undergo biopsies to diagnose the disease. The new system deciphers levels of biomarker substances in lesions, adding consistent, quantitative information to assessments currently based on visual appearance alone. In particular, changes in the concentration and distribution of eumelanin (gives color to skin) and hemoglobin are strong indicators of melanoma.

"There can be a huge lag-time before doctors even figure out what is going on with the patient," said Prof. Wong, "Our goal is to shorten that process." The AI system was trained using tens of thousands of skin images and their corresponding eumelanin and hemoglobin levels. It gives doctors objective information on lesion characteristics to help them identify or rule out melanoma before deciding if to take more invasive action. The technology could be available to doctors as early as 2018.

The research was recently presented at the 14th International Conference on Image Analysis and Recognition (ICIAR 2017, July 5-7, 2017, Montreal, Canada).

Related Links:
University of Waterloo


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.